Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy

US10501803B2 · kind B2 · utility

Assignees

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US
• JUSTUS-LIEBIG-UNIVERSITAET GIESSEN · DE

Inventors

• Guillermo BARRETO · Karben, DE
• Aditi MEHTA · Bad Nauheim, DE
• Indrabahadur SINGH · Friedberg, DE
• Marten SZIBOR · Espoo, FI
• Rajkumar SAVAI · Bad Nauheim, DE
• Werner Seeger · Gießen, DE
• Thomas Braun · Biberach, DE
• Andreas GÜNTHER · Gießen, DE
• Marcus KRÜGER · Bad Nauheim, DE

Key dates

• Filing date: May 21, 2014
• Grant date: Dec 10, 2019
• Expiry date: Sep 17, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.